Motorola Solutions raises annual revenue forecast on steady demand
Government agencies and businesses have been making efforts to strengthen their security and communication infrastructure, aiming to prevent disruptions to operations caused by cyberattacks, benefiting Motorola.
The verticals that drive Motorola's enterprise security business are healthcare, critical infrastructure and education, which are markets that tend to be more resilient.
To address the impact of tariffs, Motorola has been implementing discretionary cost controls, adjusting its supply chain and increasing pricing across its portfolio.
The company makes radio communication equipment, 911 emergency call handling software and body cameras widely used by law enforcement agencies in the United States and globally.
Motorola has also expanded into video surveillance and data analytics, integrating these technologies into its tools for public safety and first responders.
In July, the company said it will introduce AI labels across its safety and security products to enhance transparency around the use of artificial intelligence in public safety and enterprise security.
The company closed its acquisition of wireless-radio maker Silvus Technologies for $4.4 billion on Wednesday, aiming to strengthen its market position and capitalize on rising demand.
Motorola now forecasts fiscal 2025 revenue growth of 7.7% to about $11.65 billion, including expected revenue related to Silvus, higher than its prior projection of a 5.5% growth. Analysts expect $11.41 billion in revenue, according to data compiled by LSEG.
Its revenue for the second quarter was $2.77 billion, compared with an estimate of $2.73 billion.
Adjusted quarterly profit was $3.75 per share, up from $3.24 a year ago.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
an hour ago
- The Guardian
Parents in the US: how are tariffs affecting prices for back-to-school supplies?
We want to hear from families in the US. As the new school year approaches, have you noticed rises in the cost of back-to-school items? How have prices changed recently? What has been the effect on your family? Since taking office in January, Donald Trump's tariff policies have upended trading relationships, rattled global markets and stoked fears of inflation. The latest wave of the president's tariffs came into force on 8 August – and more than 60 countries around the world are scrambling to respond. The US is still threatening major tariffs on China, and other major foreign suppliers of US goods are already working out how to pass on the costs of the levies. Business leaders have warned that Trump's high, volatile tariffs will force companies to raise US consumer prices. Tariffs are already affecting prices at retailers including Walmart and Best Buy. How has the cost of getting ready for school affected you? You can tell us about shopping for back-to-school supplies by filling in the form below. Please include as much detail as possible. Please include as much detail as possible. Please include as much detail as possible. Please note, the maximum file size is 5.7 MB. Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian. Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian. If you include other people's names please ask them first. Contact us on WhatsApp or Signal at +447766780300. For more information, please see our guidance on contacting us via WhatsApp, For true anonymity please use our SecureDrop service instead. If you're having trouble using the form click here. Read terms of service here and privacy policy here.
Times
an hour ago
- Times
NHS drug pricing gives cold comfort to Big Pharma
When the government launched its Life Sciences Sector Plan on July 16 the tone was buoyant and the aim impressive: to turn 'cutting-edge research into real-world results: new treatments, faster diagnosis, and more lives saved'. The 'roadmap' to these sunlit uplands was constructed around three 'core pillars': to enable world-class scientific research and development; to attract global capital and grow UK companies; and to deliver better outcomes for patients in a more modern, preventive healthcare system. Few would dare to argue with these noble aspirations. And the UK's life sciences industry, which is worth £108 billion and employs more than 300,000 people, has indeed long been seen as a jewel in the country's economic crown. But the shadow of potential decline has fallen across it in recent years, with a cautionary tale attached: its name is AstraZeneca. Britain's most valuable public company, presently worth £170 billion, has deep roots in this country: it was the result of a 1999 merger between Sweden's Astra and the UK's Zeneca Group, itself an offshoot of the British chemical behemoth ICI. Its chief executive, Sir Pascal Soriot, in situ since 2012, has shown a strong commitment to nurturing scientific discovery. That yielded its most dramatic benefits during the Covid-19 pandemic when AstraZeneca's vaccine, developed with Oxford University, was a British success story. Yet since then its relations with the UK government have not all been smooth sailing. In 2021, as a response to Britain's 'discouraging' taxes, the company located a £320 million new factory in Ireland rather than England. Sir Pascal was also unhappy with the decision by Nice, England's drug-approval body, to reject the firm's breast cancer drug Enhertu on cost grounds, despite its adoption in Scotland. Perhaps the most dispiriting episode, however, involved AstraZeneca's decision to abandon a proposed £450 million expansion of its vaccine plant in Speke, near Liverpool, after the incoming Labour government threatened to slash the subsidies it was previously offered. There have been worrisome murmurs of relisting in the US. • AstraZeneca boss demands big rise in NHS drug spending Those examples — and the dissatisfaction they indicate — have echoes in the wider mood in the life sciences industry. Many pharmaceutical companies feel that the UK has moved from striking a necessarily hard bargain on NHS drug prices to a resistant mindset that overly restricts patients' access to new treatments. Last year Paul Hudson, the British chief executive of the French company Sanofi, lamented a UK system that is slow to pass on medical advances: for every 100 patients that get a new medicine within its first year of production in EU countries, he said, only 21 UK patients enjoy the same benefit. The share of the UK health budget spent on new medicines has fallen to less than 10 per cent, compared with 15 per cent in France and 17 per cent in Germany. Meanwhile, companies say, overly tight NHS price-capping on drugs is now threatening investment in Britain. Clearly a balance must be struck between NHS budgetary restraints and encouraging life-changing research and development. Yet the warnings from AstraZeneca suggest that the pharmaceutical industry is being viewed through too myopic and punitive a lens, because it is easier to seek discounts on drugs than it is to improve NHS efficiency.
Reuters
2 hours ago
- Reuters
TV broadcaster Nexstar in advanced talks to acquire rival Tegna, source says
Aug 8 (Reuters) - Television broadcaster Nexstar Media Group (NXST.O), opens new tab is in advanced talks to acquire rival Tegna (TGNA.N), opens new tab, a person familiar with the matter told Reuters on Friday. Shares of Tegna surged 30% in extended trading following the report, while Nexstar's shares were largely flat. A potential deal between the two companies would mark a significant step in the ongoing consolidation of the U.S. television industry, as broadcasters adapt to shifting consumer habits driven by cord-cutting and the rapid expansion of streaming, amid expectations of looser regulations under U.S. President Donald Trump's administration. Nexstar, owns or partners with over 200 stations in 116 markets. It also operates high-profile media properties including The CW and NewsNation, and has recently increased its focus on sports content. Tegna owns 64 stations and operates networks such as True Crime Network. The company has a market valuation of approximately $2.42 billion, compared with Nexstar's $5.56 billion, according to LSEG data. The Wall Street Journal, which first reported the talks, said a deal could be finalized soon, provided negotiations avoid last-minute obstacles. Both Nexstar and Tegna declined to comment on the report. Tegna has been subject to takeover interest in the past. In 2022, it agreed to be taken private by Standard General in a deal valued at $8.6 billion, including debt, but later terminated the merger agreement following regulatory scrutiny.
